← Back to Screener
AN2 Therapeutics, Inc. Common Stock (ANTX)
Price$3.14
Favorite Metrics
Price vs S&P 500 (26W)148.73%
Price vs S&P 500 (4W)-35.26%
Market Capitalization$117.17M
All Metrics
Book Value / Share (Quarterly)$1.94
P/TBV (Annual)5.38x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.09
Price vs S&P 500 (YTD)183.32%
EPS (TTM)$-1.16
10-Day Avg Trading Volume0.42M
EPS Excl Extra (TTM)$-1.16
EPS (Annual)$-1.16
ROI (Annual)-66.29%
Cash / Share (Quarterly)$2.12
ROA (Last FY)-56.78%
EBITD / Share (TTM)$-1.26
ROE (5Y Avg)-51.73%
Cash Flow / Share (Annual)$-1.09
P/B Ratio2.21x
P/B Ratio (Quarterly)0.59x
Net Income / Employee (Annual)$-2
ROA (TTM)-49.13%
EPS Incl Extra (Annual)$-1.16
Current Ratio (Annual)6.87x
Quick Ratio (Quarterly)6.65x
3-Month Avg Trading Volume0.99M
52-Week Price Return148.85%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.67
52-Week High$6.91
EPS Excl Extra (Annual)$-1.16
26-Week Price Return152.71%
Quick Ratio (Annual)6.65x
13-Week Price Return185.96%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.87x
Enterprise Value$97.227
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.12
3-Month Return Std Dev234.99%
Net Income / Employee (TTM)$-2
ROE (Last FY)-66.29%
EPS Basic Excl Extra (Annual)$-1.16
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.16
ROI (TTM)-55.04%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.92
Price vs S&P 500 (52W)119.02%
Year-to-Date Return185.96%
5-Day Price Return6.89%
EPS Normalized (Annual)$-1.16
ROA (5Y Avg)-46.42%
Month-to-Date Return-4.68%
EBITD / Share (Annual)$-1.26
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-51.73%
EPS Basic Excl Extra (TTM)$-1.16
P/TBV (Quarterly)3.69x
P/B Ratio (Annual)0.59x
Book Value / Share (Annual)$1.94
Price vs S&P 500 (13W)185.28%
Beta-1.34x
Revenue / Share (TTM)$0.00
ROE (TTM)-55.04%
52-Week Low$1.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ANTXAN2 Therapeutics, Inc. Common Stock | — | — | — | — | $3.14 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
AN2 Therapeutics develops small molecule therapeutics using proprietary boron chemistry, targeting infectious diseases and oncology with significant unmet medical needs. Its pipeline includes programs for Chagas disease, non-tuberculous mycobacterial infections, and melioidosis, with additional early-stage oncology initiatives.